Commit Biologics
Aarhus, Central Denmark Region, Denmark · Biotechnology, Health Care, Therapeutics · 20 employees
Commit Biologics is a company specializing in activating the complement system to treat cancer and autoimmune diseases using their unique Bispecific Complement Engaging (BiCE™) platform.
Funding history
- Series seed — $5.5M — Feb 2025
- Series seed — $16.0M — May 2024
Recent signals
- Mar 11, 2026: Commit Biologics Appoints Thomas L. F. Montgomery Andresen as Chief Executive Officer
- Feb 02, 2025: Commit Biologics Appoints Mikkel Wandahl Pedersen as Interim CEO
- Feb 01, 2025: Raised $5.5M in Series seed
- Oct 15, 2024: Commit Biologics Appoints Mikkel Wandahl Pedersen as Chief Scientific Officer
- May 10, 2024: Raised $16.0M in Series seed
See plans & pricing → Track Commit Biologics’s funding, hiring, and signals — with verified contacts — on Fundz.